Trial Profile
A randomized, double-blind, placebo-controlled study of risperidone monotherapy in ambulatory bipolar disorder with concurrent moderately severe anxiety and lifetime panic or generalized anxiety disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Bipolar disorders; Generalised anxiety disorder; Panic disorder
- Focus Therapeutic Use
- 21 Jun 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 21 Jun 2011 Actual initiation date (Feb 2004) added as reported by ClinicalTrials.gov.
- 01 Jun 2009 Results published in the Journal of Affective Disorders.